Spotlight on Pathology

Jacob Sands, MD
Credits: 1.0 CME / CC
TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target
Jacob Sands, MD
Vindico Medical Education

TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pathology Presentations

Jacob Sands, MD
1.0 CME / CC
Vindico Medical Education
TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target

TROP2 in Non-Small Cell Lung Cancer: A Novel Therapeutic Target

Start

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABPath CC Point(s)
Released: March 31, 2022
Expires: March 30, 2023
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other health care professionals involved in the management of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the role of trophoblast cell surface antigen 2 (TROP2) in tumor biology as well as its implications as a cancer biomarker.
  • Describe how novel antibody drug conjugates exploit TROP2 as an anticancer therapy.
  • Examine current unmet needs for patients with NSCLC without actionable mutations.
  • Assess the latest clinical safety and efficacy regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior treatment.

Activity Description

For patients with non-small cell lung cancer (NSCLC) who do not have actionable genomic alterations, programmed death ligand 1 immunotherapy, with or without platinum-based chemotherapy, is the standard of care. These regimens have demonstrated clear clinical benefit, yet 40% to 60% of patients do not respond to these initial therapies, or eventually experience disease progression. Options are limited for these patients, but novel therapies, such as antibody drug conjugates that target trophoblast cell surface antigen 2 (TROP2), are currently under clinical investigation. TROP2 is expressed in approximately 70% of NSCLC tumors, and expression has been associated with poor outcomes. In this continuing medical education activity, experts in the field will review current unmet needs for patients with NSCLC without actionable mutations, discuss the role of TROP2 in tumor biology and its implications as a cancer biomarker, and assess the most recent clinical safety and efficacy data regarding new and emerging TROP2 antibody drug conjugates for the management of patients with NSCLC who have progressed on prior therapies.

Topic

  • Introduction
  • TROP2: Role in Tumor Biology and Implications for Biomarker (Jacob Sands, MD)
  • Second-line Therapy for Patients With Non-Small Cell Lung Cancer: Unmet Needs (Benjamin P. Levy, MD)
  • Advances in TROP2-Targeted Therapies for Patients With Non-Small Cell Lung Cancer (Rebecca Heist, MD)
  • Conclusion by Activity Chair

Activity Chair

Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, MA

Disclosure:
Consultant: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Takeda

Faculty

Rebecca Heist, MD
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosure:
Consultant: AbbVie, Daichii Sankyo, EMD Serono, Novartis
Independent Research Contractor (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Exelixis, Lilly, Mirati, Novartis, Turning Point


Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Washington, DC

Disclosure:
Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck, Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Pathology’s (ABPath) Continuing Certification program and earn up to 1.0 CC points. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting Continuing Certification credit within approximately 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, March 31, 2022, to March 30, 2023.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com